← ANALYST RATINGS · TIPRANKS
Denali Therapeutics (DNLI): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy0 Hold0 Sell
Ratings of 8 analysts in the last 3 months · top analysts only12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $37.67, the highest $42.00, the lowest $29.00. The average is +113.9% from the last price of $17.61.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $19.00 → $18.50−2.6% | Hold | +5.1% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $18.50 → $18.00−2.7% | Hold | +2.2% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $19.50 → $18.50−5.1% | Hold | +5.1% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $18.50 → $17.50−5.4% | Hold | −0.6% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $19.50 → $19.00−2.6% | Hold | +7.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $19.00 → $18.50−2.6% | Hold | +5.1% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $30.00 → $35.00+16.7% | Buy | +98.8% | Reiterated | 25.08.26on TipRanks 08:40 | +2.7%next day −1.5% · 5 days −6.1% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $29.00 | Buy | +64.7% | Reiterated | 11.08.26on TipRanks 07:55 | −0.9%next day +2.1% · 5 days −1.1% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $42.00 | Buy | +138.5% | Reiterated | 07.08.26on TipRanks 15:05 | −0.2%next day +0.7% · 5 days −2.1% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $25.00 → $34.00+36.0% | Buy | +93.1% | Assigned | 07.08.26on TipRanks 09:10 | −0.2%next day +0.7% · 5 days −2.1% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $36.00 → $40.00+11.1% | Buy | +127.1% | Assigned | 07.08.26on TipRanks 08:20 | −0.2%next day +0.7% · 5 days −2.1% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $41.00 | Buy | +132.8% | Reiterated | 07.08.26on TipRanks 08:15 | −0.2%next day +0.7% · 5 days −2.1% | ↗ |
| Charles Moore★★★★★★★★★★#5625 · hits 71% · avg +14.1% | Robert W. Baird | $31.00 → $34.00+9.7% | Buy | +93.1% | Reiterated | 07.08.26on TipRanks 08:01 | −0.2%next day +0.7% · 5 days −2.1% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $31.00 | Buy | +76.0% | Reiterated | 07.08.26on TipRanks 06:50 | −0.2%next day +0.7% · 5 days −2.1% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 07.08.26on TipRanks 03:35 | −0.2%next day +0.7% · 5 days −2.1% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $39.00 | Buy | +121.5% | Reiterated | 06.08.26on TipRanks Aug 7 07:10 | +1.4%next day −0.2% · 5 days −0.8% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 06.08.26on TipRanks Aug 7 04:00 | +1.4%next day −0.2% · 5 days −0.8% | ↗ |
| Unknown Analyst | Goldman Sachs | $41.00 | Buy | +132.8% | Reiterated | 20.07.26on TipRanks Jul 23 21:16 | −1.5%next day +3.2% · 5 days +3.3% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $31.00 → $35.00+12.9% | Buy | +98.8% | Assigned | 16.07.26on TipRanks 04:30 | −0.7%next day +3.5% · 5 days +4.7% | ↗ |
| Unknown Analyst | Jefferies | $40.00 | Buy | +127.1% | Reiterated | 13.07.26on TipRanks 10:02 | +3.9%next day −14.8% · 5 days −12.6% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $20.00 → $26.00+30.0% | Buy | +47.6% | Reiterated | 13.07.26on TipRanks 08:10 | +3.9%next day −14.8% · 5 days −12.6% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $35.00 → $40.00+14.3% | Buy | +127.1% | Reiterated | 11.05.26on TipRanks 08:10 | 0.0%next day −0.9% · 5 days −6.4% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | — | Hold | — | Initiated | 23.02.26on TipRanks 20:03 | +2.0%next day +3.2% · 5 days −5.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Denali Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $35.92 at a price of $20.67 (+73.8%); now: $36.60 at $17.61 (+107.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 10 | 12 | 8 | 8 | 4 |
| Buy | 7 | 4 | 6 | 6 | 6 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.37 (from $-0.88 to $0.37). Last quarter: $-0.68.
Best top-analyst consensus in the sector · Healthcare
About Denali Therapeutics
- CEO: Ryan J. Watts
- Employees: 503
- 161 Oyster Point Boulevard, South San Francisco, CA, 94080, US
- www.denalitherapeutics.com
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Data from the stock’s TipRanks forecast page, read 10 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗